Literature DB >> 27318821

Analgesic efficacy of celecoxib in patients after oral surgery: special reference to time to onset of analgesia and duration of analgesic effect.

Takayuki Aoki1, Yoshihide Ota2, Yusuke Mori2,3, Mitsunobu Otsuru2, Mikio Ota4, Akihiro Kaneko2.   

Abstract

PURPOSE: Cyclooxygenase-2 inhibitor celecoxib is also used in the dental field for analgesia. However, there are few reports on the time to onset and duration of analgesia. We investigated the analgesic effect of celecoxib after oral surgery.
METHODS: A total of 138 patients undergoing unilateral mandibular third molar surgery under local anesthesia were enrolled. After surgery, the patients who felt pain and requested an analgesic were instructed to take celecoxib 400 mg and to record the time. Primary efficacy outcome measures were time to onset of analgesia. In addition, the conditions of pain at the time of taking celecoxib, at the onset time of analgesia, and 2 and 6 h after taking the drug were recorded. Pain assessments were evaluated using a 10-cm visual analog scale and four-point verbal rating score. These data were documented in the questionnaire forms handed to the patients and retrieved by post.
RESULTS: Effective responses without missing were returned from 103 patients. The median time to onset of the efficacy was 35 min. The pain scales at celecoxib administration was significantly higher compared with the time of onset of analgesia, 2 hours after administraton and 6 hours hours administration (P<0.05, respectively). The pain scales at the onset time of analgesia were significantly higher compared to that after 2 or 6 h of taking the drug (P<0.05, respectively). There were no statistically significant differences in the pain scales between 2 and 6 h after taking the drug (P>0.05).
CONCLUSION: The analgesic effect of celecoxib was exhibited quickly and sustained after oral surgery.

Entities:  

Keywords:  Celecoxib; Duration of analgesic effect; Oral surgery; Time to onset of analgesia

Mesh:

Substances:

Year:  2016        PMID: 27318821     DOI: 10.1007/s10006-016-0565-2

Source DB:  PubMed          Journal:  Oral Maxillofac Surg        ISSN: 1865-1550


  22 in total

1.  A comparison of rofecoxib versus celecoxib in treating pain after dental surgery: a single-center, randomized, double-blind, placebo- and active-comparator-controlled, parallel-group, single-dose study using the dental impaction pain model.

Authors:  Kerstin Malmstrom; James R Fricke; Paul Kotey; Barbara Kress; Briggs Morrison
Journal:  Clin Ther       Date:  2002-10       Impact factor: 3.393

Review 2.  Efficacy and safety of the selective cyclooxygenase-2 inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthritis in Japan.

Authors:  Choitsu Sakamoto; Satoshi Soen
Journal:  Digestion       Date:  2010-11-01       Impact factor: 3.216

Review 3.  Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials.

Authors:  Jingjing Zhang; Eric L Ding; Yiqing Song
Journal:  JAMA       Date:  2006-09-12       Impact factor: 56.272

4.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors:  F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272

5.  TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue.

Authors:  D A Kujubu; B S Fletcher; B C Varnum; R W Lim; H R Herschman
Journal:  J Biol Chem       Date:  1991-07-15       Impact factor: 5.157

Review 6.  Single dose oral analgesics for acute postoperative pain in adults.

Authors:  R Andrew Moore; Sheena Derry; Henry J McQuay; Philip J Wiffen
Journal:  Cochrane Database Syst Rev       Date:  2011-09-07

7.  Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.

Authors:  Francis K L Chan; Angel Lanas; James Scheiman; Manuela F Berger; Ha Nguyen; Jay L Goldstein
Journal:  Lancet       Date:  2010-06-16       Impact factor: 79.321

8.  Premedication with cyclooxygenase-2 inhibitor meloxicam reduced postoperative pain in patients after oral surgery.

Authors:  T Aoki; H Yamaguchi; H Naito; K Shiiki; K Izawa; Y Ota; H Sakamoto; A Kaneko
Journal:  Int J Oral Maxillofac Surg       Date:  2006-03-15       Impact factor: 2.789

9.  A single preoperative oral dose of valdecoxib, a new cyclooxygenase-2 specific inhibitor, relieves post-oral surgery or bunionectomy pain.

Authors:  Paul J Desjardins; Vincent S Shu; David P Recker; Kenneth M Verburg; Clifford J Woolf
Journal:  Anesthesiology       Date:  2002-09       Impact factor: 7.892

10.  In vivo selectivity of a selective cyclooxygenase 2 inhibitor in the oral surgery model.

Authors:  Asma A Khan; Jaime S Brahim; Janet S Rowan; Raymond A Dionne
Journal:  Clin Pharmacol Ther       Date:  2002-07       Impact factor: 6.875

View more
  2 in total

1.  RT-qPCR study of COX-1 and -2 genes in oral surgical model comparing single-dose preemptive ibuprofen and etoricoxib: A randomized clinical trialy.

Authors:  Assis-Filipe Medeiros-Albuquerque; Cristiane-Sá Roriz-Fonteles; José-Jackson do Nascimento-Costa; José-Roberto Viana-Silva; Paulo-Goberlânio de Barros-Silva; Eduardo-Costa Studart-Soares; Filipe-Nobre Chaves; Karuza-Maria Alves-Pereira; Thyciana-Rodrigues Ribeiro; Fábio-Wildson Gurgel-Costa
Journal:  J Clin Exp Dent       Date:  2020-04-01

2.  Preemptive analgesia after lumbar spine surgery by pregabalin and celecoxib: a prospective study.

Authors:  Nguyen Trung Kien; Phillip Geiger; Hoang Van Chuong; Nguyen Manh Cuong; Ngo Van Dinh; Dinh Cong Pho; Vu The Anh; Nguyen Truong Giang
Journal:  Drug Des Devel Ther       Date:  2019-07-03       Impact factor: 4.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.